US · Healthcare · Biotechnology
EPS came in at -0.66 against a street estimate of -0.64 — a miss of 3.1%.
Analysts rate Sionna Therapeutics, Inc. Common Stock a hold (2 buy, 10 hold, 0 sell out of 12) with an average price target of $21.00.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 21.91% |
| TPG GP A, LLC | 14.37% |
| Viking Global Investors LP | 7.07% |
| Atlas Venture Life Science Advisors, LLC | 6.63% |
| Orbimed Advisors LLC | 5.65% |
| Enavate Sciences GP, LLC | 5.48% |
| Adage Capital Partners Gp LLC | 3.54% |
| JPMorgan Chase & Co | 3.30% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sionna Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.